Prostate cancer: progression of prostate-specific antigen after external beam irradiation

被引:5
作者
Dayananda, PWA
Taylor, JMG
Whiting, DG
机构
[1] Univ St Thomas, Dept Math, St Paul, MN 55105 USA
[2] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA
关键词
prostate cancer; prostate-specific antigen; deterministic model; discrete stochastic model; distribution of prostate-specific antigen level;
D O I
10.1016/S0025-5564(02)00215-8
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This paper is concerned with the development of a stochastic path of prostate-specific antigen (PSA) level after radiation treatment for prostate cancer. PSA is a biomarker for prostate cancer, higher levels of which indicate the seriousness of the cancer progression. Following the deterministic modeling of the data by the previous authors, Cox et al. [1], this paper is concerned with the theoretical knowledge that could be gained by the stochastic modeling in discrete form of the PSA path over time. The expected value of the PSA level is computed and compared with the deterministic model and it is found that they are the same for about the first year after radiation therapy. The American Society for Therapeutic Radiology has set a consensus panel definition of biochemical failure following radiation therapy: the rise in three consecutive levels of PSA is considered to be a failure of the radiation therapy. Knowledge of the path of PSA presented in this paper would be useful in the management of the radiation treatment and in particular assessing quantitatively any clinically based policy for defining recurrence after radiation therapy. Application of the model is illustrated by fitting it to clinical data available in the University of Michigan cancer center. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 7 条
[1]  
[Anonymous], MATH MODELS CANC RES
[2]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[3]  
COX RS, 1993, INT J RADIAT ONCOL, V28, P23
[4]  
KAPLAN ID, 1991, CANCER, V68, P400, DOI 10.1002/1097-0142(19910715)68:2<400::AID-CNCR2820680231>3.0.CO
[5]  
2-Z
[6]  
ZAGARS GK, 1993, CANCER-AM CANCER SOC, V72, P832, DOI 10.1002/1097-0142(19930801)72:3<832::AID-CNCR2820720332>3.0.CO
[7]  
2-6